New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 19, 2014
16:07 EDTACHNAchillion granted U.S. patent for ACH-3102, structurally related NS5A inhibitors
Achillion Pharmaceuticals announced that the U.S. Patent & Trademark Office has granted Achillion U.S. Patent No. 8,809,313, covering composition-of-matter and method of use claims for ACH-3102 and structurally related NS5A inhibitor compounds. ACH-3102 is Achillion's second generation phase 2 NS5A inhibitor being investigated for the treatment of chronic hepatitis C virus, or HCV, infection. This patent is entitled "Substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes useful for treating HCV infections," and provides a patent term which lasts until 2032.
News For ACHN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 24, 2015
10:34 EDTACHNAchillion March calls active on renewed takeover chatter
Achillion March 14 and April 15 calls are active on total call volume of 1,600 contracts (100 puts) on renewed takeover chatter. February weekly call option implied volatility is at 82, March and April is at 79, June is at 81; compared to its 10-week average of 81 according to Track Data. Active call volume suggests traders taking positions for large near term price movement.
10:22 EDTACHNRumor: Achillion moves positive on renewed takeover chatter
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use